Interferon-gamma responses to ESAT-6 in tuberculosis patients early into and after anti-tuberculosis treatment.
Int J Tuberc Lung Dis
; 9(9): 1034-9, 2005 Sep.
Article
en En
| MEDLINE
| ID: mdl-16158897
ABSTRACT
OBJECTIVE:
To investigate T-cell responses to ESAT-6 by an interferon-gamma (IFN-gamma) ex vivo enzyme-linked immunospot (ELISpot) assay in tuberculosis (TB) patients early during treatment and in patients who have completed a course of anti-tuberculosis chemotherapy.DESIGN:
T-cell responses following overnight stimulation with 6-kD early secretory antigenic target (ESAT-6) antigen were compared to responses obtained using cells cultured with ESAT-6 for 6 days, using an ELISpot assay.RESULTS:
In the ex vivo ELISpot assay, the median IFN-gamma responses in TB patients, irrespective of treatment status, were significantly higher than in healthy BCG-vaccinated controls. In the 6-day ELISpot assay, median IFN-gamma responses were significantly higher in TB patients who had completed treatment than in patients early during therapy. There was considerable individual variability in the degree of expansion of ESAT-6 specific T-cells from day 1 to day 6 in both treatment groups.CONCLUSION:
Further studies are required to assess which type of assay provides the best indicator of a memory T-cell response and how ESAT-6 specific T-cells relate to protective immunity in TB infection.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Tuberculosis
/
Linfocitos T
/
Técnicas para Inmunoenzimas
/
Interferón gamma
/
Mycobacterium tuberculosis
/
Antígenos Bacterianos
Límite:
Adult
/
Humans
/
Middle aged
Idioma:
En
Revista:
Int J Tuberc Lung Dis
Año:
2005
Tipo del documento:
Article
País de afiliación:
Reino Unido